A statistically normal pressure does not exclude glaucoma. Confirm the pattern and progression; individualised IOP lowering remains the established disease-directed treatment. Treat systemic disease for its own indications without promising visual protection from blood-flow manipulation.
Terminology and draft status
Original terms and source questions remain documented. Selected Arabic terms were checked in WHO UMD; exact searches for normal-tension glaucoma and low-tension glaucoma returned no result. The NTG term remains a working translation. Further source, translation and medical review remain pending.
01Recognise NTG within the open-angle glaucoma spectrum
Normal-tension glaucoma (NTG) describes characteristic glaucomatous optic neuropathy and visual-field damage with untreated pressure measurements within the statistical normal range. It lies on the primary open-angle glaucoma (POAG) spectrum rather than constituting proof of a pressure-independent disease. 1
Mechanical susceptibility at the lamina cribrosa and vascular factors are plausible contributors. Disc haemorrhage and paracentral defects can be prominent, but no single feature identifies the mechanism in an individual eye. Preserve uncertainty rather than equating an association with a proven treatment target. 1
Evidence from broader open-angle glaucoma populations must be applied cautiously when baseline pressure is already low. Distinguish an NTG pressure-lowering decision from secondary pressure elevation after vitreoretinal surgery; the mechanism, target and evidence population differ. 1
02Confirm the pattern and investigate atypical findings
Repeat reliable applanation pressure measurements and review prior untreated values, timing, medication and corneal factors. Central corneal thickness helps interpret tonometry; numerical correction formulas are not a substitute for judgement. Gonioscopy confirms angle anatomy and looks for a secondary mechanism. 1
Document the disc with photographs and assess the retinal nerve fibre layer (RNFL), optical coherence tomography (OCT) and visual fields together. Check segmentation, myopia, reliability and structure–function agreement before diagnosing progression. Neither structural imaging nor perimetry is dispensable because one test appears normal. 1
A diurnal or 24-hour profile may answer a question about missed pressure peaks, but is not a mandatory test in every suspected NTG case. Use serial high-quality tests and a risk-adapted schedule to estimate progression; fixed intervals alone cannot establish stability. 1
Atypical acuity or colour loss, disproportionate optic pallor, unexplained rapid change or neurological symptoms should prompt reassessment for another optic neuropathy and targeted neuro-ophthalmic investigation. 1 19
Compression, inflammation and other causes are clinical differentials; low cerebrospinal-fluid pressure remains a mechanistic hypothesis, not an instruction for routine lumbar puncture. 1 19
03Lower pressure for the individual risk: interpret CNTGS
CNTGS randomised 145 selected NTG eyes to observation or a 30% pressure-reduction goal. Progression was 22/66 versus 31/79 (p=0.21); cataract-censored analysis reported 8/66 versus 21/79. 2
The different analyses and excess surgical cataract must accompany any treatment-benefit claim. 2
The trial included eyes with documented progression, a new disc haemorrhage or fixation-threatening defects; it does not establish the same benefit for every stable suspect. Some untreated eyes remain stable for long periods. 1 2
Treatment must balance the rate of damage and lifetime visual risk against adverse effects and surgical harm. 1 2
The original minimum 20–30% rule is not a universal NTG threshold. Use the untreated baseline, damage, progression, life expectancy and tolerability to set and revisit the target for each eye. A percentage reduction is a goal, not a guaranteed response; the absolute pressure still matters. 1 2
Choose medication, suitable laser or surgery according to the required reduction, angle, ocular surface, adherence and systemic contraindications. Progression despite apparent control calls for confirmation and reassessment, not automatic escalation based on a single OCT or field. 1
04Assess systemic disease and nocturnal blood pressure
Ask about migraine, Raynaud phenomena, cardiovascular treatment and symptoms suggesting excessive hypotension. A prospective 85-patient NTG cohort associated nocturnal hypotension with subsequent field progression. 1 3
This is not proof that raising systemic pressure or changing evening medication prevents glaucoma damage. 1 3
Investigate suspected sleep apnoea and other comorbidities with the appropriate team and treat according to their own indications. Exercise and a balanced diet support general health; neither they nor blood-flow testing replace pressure treatment or progression monitoring. 1
No established vascular optimisation or neuroprotective regimen is offered as proven visual preservation here. 1
05SLT: select suitable eyes and interpret the trials
Selective laser trabeculoplasty (SLT) can be an initial or adjunct option in suitable open-angle disease. Cytokine signalling and trabecular remodelling explain a proposed biological mechanism; “no anatomical damage” is too absolute. 1 4 5
Inflammation, transient pressure rise and non-response remain possible, and lower baseline pressure may limit the absolute reduction. 1 4 5
LiGHT China is a separate trial, not a subgroup of the UK LiGHT study. Baseline age, myopia and severity affect applicability; a cohort comparison does not prove an ethnic treatment effect. 6 7
The repeat-SLT analysis selected 180 eyes of 105 participants and was post hoc, with different pretreatment pressures and no random allocation to initial versus repeat treatment. 6 7
In the UK exploratory analysis, secondary SLT followed at least 3 years of drops. Switching stable eyes reduced medication burden; escalating uncontrolled eyes could add pressure control but did not eliminate surgery. 8
These were different indications, not a randomised SLT-switch versus intensified-medication comparison. 8
The masked multicentre Swedish OSLT trial enrolled 400 patients and compared 180°/360° standard/high protocols. At 1–6 months, 360/high reduced pressure by 5.4 mmHg versus 3.4/3.2/4.2 mmHg; 6-month success was 58.3% versus 30.2/29.3/41.7%. 9
More transient discomfort accompanied the strongest protocol; this is not proof of superiority in every NTG eye. 9
Energy in OSLT was titrated to a tissue response rather than one fixed pulse setting. The lecture’s means 0.95 versus 0.71 mJ remain original values requiring their exact source; they are not a universal operative prescription. Repeat treatment, previous response, angle anatomy, pigmentation and pressure monitoring require individual assessment. 1 9
| Parameter | Trial/lecture context | Clinical meaning and limit |
|---|---|---|
| Extent | OSLT compared 180° and 360° with standard/high protocols | 360/high performed best in this trial; not a universal NTG result |
| Energy | Original means 0.95 versus 0.71 mJ remain unreconciled | Titrate to tissue response and device guidance; means are not mandatory settings |
| Repeat treatment | Effect can wane; repeat SLT is a separate decision | Assess angle, prior response, baseline pressure, follow-up and study selection |
06MIGS: distinguish mechanism, study design and applicability
Minimally invasive glaucoma surgery (MIGS) includes different mechanisms and devices; it is not one interchangeable intervention. HORIZON tested Hydrus added to cataract surgery against cataract surgery alone in selected POAG, not stand-alone surgery in NTG. 1 18
Weigh the required target, medication burden, cost, adverse effects and distal outflow rather than assuming a universal step between laser and filtration. 1 18
A 2026 systematic review of 16 MIGS RCTs with 4562 participants reported mean fragility index 9.4 and fragility quotient 0.031. It selected significant binary outcomes. Fragility is not effect size or proof that every device is ineffective; interpret it alongside attrition, uncertainty and the clinical comparison. 10
The Manchester study followed phacoemulsification plus a first-generation iStent without a control group: 41 patients entered and 19 remained at 84 months (7 years). 11
Reported pressure/drop reductions are limited by attrition, selection and cataract-surgery effects. They do not establish the same long-term benefit for every iStent model or NTG patient. 11
Pahlitzsch compared stand-alone SLT, Trabectome and iStent inject retrospectively using propensity matching and 3-year follow-up. Similar measured pressure outcomes do not establish equivalence. 12
Choice of procedure, residual confounding, differing eligibility and the success definition remain important when interpreting “no difference”. 12
| Feature | SLT | Trabecular MIGS / bypass |
|---|---|---|
| Primary mechanism | Biological signalling/remodelling; a simplified model | Anatomical bypass or tissue removal; device-specific |
| Anatomy | No intentional incisional opening; not a guarantee of no tissue effects | Trabecular modification/bypass; distal outflow still matters |
| Lecture framing | Make trabecular outflow work better | Bypass part of the resistance; not proof that all outflow problems are solved |
07After retinal surgery: identify the pressure mechanism
Pressure elevation after pars plana vitrectomy (PPV) is secondary glaucoma context, not evidence for NTG. Timing, tamponade, inflammation, bleeding, steroid exposure and the drainage angle guide assessment. 1 15 17
The original day-one and first-week percentages use different thresholds and unresolved cohorts; they cannot be taught as one rising incidence curve. 1 15 17
The lecture orders gas expansion as C3F8 > C2F6 > SF6 > air. Preserve the mechanism, but do not turn this into a universal patient-risk ranking: concentration, fill volume, lens/angle anatomy and postoperative circumstances matter. Avoid overfill and assess a painful pressure spike promptly. 1 17
Silicone oil can cause pressure elevation through overfill, anterior migration, pupillary block, inflammation or emulsified droplets obstructing the trabecular meshwork. Long contact may leave persistent outflow damage. 1 16
A heterogeneous literature range for emulsification is not an individual risk estimate or proof of the same mechanism in every eye. 1 16
A retrospective 196-patient tamponade comparison reported consistently raised IOP with silicone oil at RR 4.70 (95% CI 1.86–11.85). Case mix, treatment selection and the outcome definition limit interpretation. 16
This is an association in a postoperative population, not an NTG trial or a universal forecast after oil injection. 16
Assess the lens, capsule, anterior hyaloid and patency/location of an iridectomy when pupillary block is possible. Aphakia and a disrupted lens barrier differ from uncomplicated pseudophakia. 1 17
The lecture’s universal inferior-iridectomy rule and closure percentage require their original operative context; they are not automatic instructions for every pseudophakic eye. 1 17
Treat pressure and inflammation according to the mechanism. Oil removal may help selected eyes but does not always reverse glaucoma and can increase retinal redetachment risk. 1
Conventional filtration has a poorer prognosis in these eyes, not certain failure; drainage devices or cyclophotocoagulation (CPC) may be alternatives, with their own complications and visual-potential considerations. 1
Neovascular glaucoma (NVG) requires treatment of retinal ischaemia as well as pressure. Examine iris and angle neovascularisation (NVI/NVA), peripheral anterior synechiae (PAS) and the retinal cause. 1 13
Clearing media does not stop the angiogenic drive; coordinate retinal photocoagulation and appropriate anti-VEGF treatment with glaucoma management. 1 13
In Sakamoto’s retrospective diabetic-vitrectomy cohort, selected model associations were NVI/NVA OR 3.93 (95% CI 1.05–14.65), insulin OR 2.09 (1.02–4.30) and tamponade OR 2.18 (1.13–4.23). 13
Wide intervals, confounding and variable selection matter. Odds ratios are not absolute patient risks or proof that tamponade causes the same risk in every eye. 13
Scott’s retrospective series combined PPV with drainage implants in 40 mixed refractory-glaucoma eyes, only 14 with NVG. Mean IOP fell from 34 to 13 mmHg at 1 year; 31/40 (77.5%) had stable/improved acuity. 14
Severe visual complications also occurred. Do not generalise these results as an Ahmed-only NVG trial. 14
08Make a joint plan and reassess the result
Before surgery, map optic nerve reserve, angle/PAS/NVI, lens status and conjunctival resources for later filtration. During surgery, plan tamponade concentration and fill, a suitable patent iridectomy when indicated, and retinal ischaemia treatment. 1 17
These are coordinated clinical decisions, not a universal operative recipe or a claim that clearing the media treats the underlying ischaemia. 1 17
RCOphth’s 2026 practice points support risk-adapted postoperative review, with very-low-certainty heterogeneous evidence. Some uncomplicated low-risk patients can omit postoperative day 1 review; glaucoma, comorbidity, tamponade and complicated surgery alter that decision. 15
Pressure prophylaxis, later review and clear emergency access must be planned; no patient should cancel a scheduled visit on the basis of this summary. 15
Continue early pressure checks when indicated, and reassess NVI/NVA and retinal perfusion in proliferative diabetic retinopathy (PDR). The original 1/3/6-month schedule is a teaching protocol, not a universal interval. 1 15 17
New pain, sudden visual loss or concerning neurological symptoms need urgent assessment; routine NTG follow-up and postoperative emergency care answer different questions. 1 15 17
| Original review topic | Evidence context | What should guide the decision? |
|---|---|---|
| SLT: China and UK | Separate trials and selected secondary analyses | Population, baseline pressure, severity and indication; do not infer ethnic superiority |
| SLT technique | OSLT standard/high and 180°/360° comparison | Clinical trial protocol is not a universal fixed-energy prescription |
| MIGS fragility | Selected statistically significant binary outcomes | Effect size, missing data and clinical importance alongside FI/FQ; original percentages require reconciliation |
| Silicone oil | Multiple pressure mechanisms; poorer filtration prognosis | No inevitable trabeculectomy failure; balance oil removal, retinal stability, GDD/CPC and visual potential |
| Post-PPV pressure spikes | Different thresholds, time windows, prophylaxis and case mix | Do not merge original percentages; gas risk depends on more than expansion order |
| NVG risk | Retrospective diabetic-vitrectomy associations | NVI/NVA, ischaemia, angle and retinal cause; original Kwon onset and timing still unresolved |
What must be checked before diagnosing NTG?
Repeated reliable pressure measurements, prior untreated values, corneal thickness, angle, characteristic structure–function agreement and alternative optic neuropathies when findings are atypical.
How does the treatment goal differ from other POAG?
Pressure lowering remains the established disease-directed strategy. Individualise the target for damage and progression; appropriately treat systemic comorbidities without promising visual benefit from blood-flow manipulation.
References and access status
- 1EGS Terminology and Guidelines for Glaucoma,6th edition (2025)
Supplied local PDF text: CNTGS pp44–45, POAG/risk pp124–125, treatment principles/target pp160–169 and vitreoretinal mechanisms p136; CCT p80 carried forward. Relevant passages only, not every figure/table or whole-book reading. DOI10.1136/bjophthalmol-2025-egsguidelines.
- 2CNTGS effectiveness/intent-to-treat report (1998),DOI10.1016/S0002-9394(98)00272-4
Complete indexed primary abstract read; main paper/supplements unread. Selection, cataract censoring and different denominators retained. Companion report not newly read in full; no silent reconciliation with EGS summary.
- 3Charlson et al. Nocturnal hypotension and glaucoma progression (2014)
Primary indexed abstract access carried forward from review009; full report unread. Observational association, not a trial of adjusting systemic treatment.
- 4LiGHT six-year UK trial (2023)
Abstract appraisal carried forward from review008; not newly read full text. Read with the2025 corrigendum; superseded surgery counts are not repeated as current evidence.
- 5LiGHT corrigendum (2025),DOI10.1016/j.ophtha.2025.07.029
Publisher-indexed correction access carried forward from review008. Complete corrected tables/pp1323–1325 still unread after direct403; no full-correction validation claimed.
- 6LiGHT China design and baseline characteristics (2021)
Primary baseline report located and indexed passages inspected; full PDF not read. Separate Chinese trial, not a UK subgroup or direct ethnic-effect comparison.
- 7LiGHT China: responsiveness/repeat SLT (2024)
Complete primary abstract, selected methods/results and extracted tables inspected. Full narrative not completely read; supplements/figure pixels unread. Post hoc selected-eye analysis with multiplicity and eye-dependence limits.
- 8LiGHT: secondary SLT after medical treatment (2025)
Complete primary abstract and selected methods/statistical/limitation passages read. Main report not fully read; supplements unread. Switch/escalation indications were not randomised against each other.
- 9Dahlgren et al. Swedish OSLT RCT (2024),DOI10.1016/j.ogla.2023.10.004
Complete primary abstract directly read; full report/rare-harm estimates unread. Titrated protocols; original exact mean energies need their source. The2025 predictor paper is post hoc, not independent replication.
- 10Ansari et al. MIGS fragility systematic review (2026),DOI10.1016/j.ajo.2026.02.024
Complete primary abstract directly read; full methods/tables/registration unread. Restricted to selected significant binary outcomes; FI/FQ do not replace effect sizes or risk-of-bias appraisal.
- 11Ziaei and Au. Manchester iStent seven-year cohort
Accessible primary abstract, narrative results/limitations and extracted table1 read; figure pixels/supplements unread. Abstract/body reductions and a table percentage differ; discrepancies remain in evidence.md. Uncontrolled combined surgery and attrition limit causal inference.
- 12Pahlitzsch et al. SLT versus MIGS (2021),DOI10.1007/s40123-021-00347-0
Complete primary abstract directly read; selected indexed main-text description only. Full PMC access challenged. Retrospective matching, residual confounding and differing abstract/figure success thresholds noted.
- 13Sakamoto et al. NVG after diabetic vitrectomy (2018),DOI10.2147/OPTH.S184959
Indexed primary tables inspected; direct PubMed incomplete/publisher403. Full methods/report unread. Model selection, confounding, wide intervals and odds versus absolute risk retained.
- 14Scott et al. Combined PPV and drainage implants (2000),DOI10.1016/S0002-9394(99)00363-3
Complete indexed primary abstract read; direct retrieval incomplete. Main article unread. Mixed refractory-glaucoma case series, not uniformly NVG/Ahmed; serious visual harms and selection matter.
- 15RCOphth. Day-one review in modern vitrectomy surgery (January2026)
Main pp1–3 read and p4 flowchart visually inspected from locally rendered official PDF. Appendix tables not fully inspected. Very-low-certainty evidence; conditional risk-based review, not a universal omission or mandatory regimen.
- 16Endotamponade comparison: retrospective196-patient study (2019)
Indexed primary result passage inspected; direct PMC challenged; full report unread. Distinguish persistently raised pressure from any rise. Exact comparator, definitions and confounding need the full report.
- 17Original derivative lecture page and three video links
Complete existing German page and companion topic read; original snapshot and all three tables retained. Videos, spoken transcript and slides not inspected; no exact spoken-term verification claimed.
- 18HORIZON five-year randomised trial (2022),DOI10.1016/j.ophtha.2022.02.021
Primary indexed abstract design/population passages inspected; full report/supplements not newly read here. Hydrus plus cataract surgery versus cataract surgery alone, not an NTG-specific stand-alone comparison.
- 19Kosior-Jarecka et al. Atypical NTG neuroimaging (2020),DOI10.1155/2020/9093206
Complete primary abstract directly read; full report unread. Selected atypical patients: imaging yield cannot be applied to all routine NTG. Targeted differential work-up, not automatic MRI/lumbar puncture.
Original lecture links
For patients
Glaucoma can damage the optic nerve even when the measured pressure seems normal. Treatment aims to reduce the risk of further loss; it does not normally restore an already lost field. Attend follow-up even when you have no symptoms.
Use prescribed treatment as agreed and tell the team about difficulties or adverse effects. Suspected sleep apnoea and other general health problems deserve assessment; exercise and balanced nutrition support health but do not replace glaucoma care.
Do not change blood-pressure tablets or cancel planned postoperative checks yourself. The eye team and your other doctors should coordinate treatment. Ask whom to contact urgently after surgery and keep that information available.
Sudden visual change with headache or neurological symptoms needs urgent assessment. Severe/increasing eye pain or sudden loss of vision after surgery also needs prompt help; do not assume it is ordinary NTG progression.